Table 1

Characteristics of the clinical trials included in the meta-analysis
First Author [Reference No.] Country Enrolment period Study* Analysis No. of patients Age, years, mean Gender,% male
Peg-IFN Peg-IFN Peg-IFN
α-2a/α-2b α-2a/α-2b α-2a/α-2b
Yenice [16] Turkey No information RCT, unblinded Per protocol 37/37 48.2 and 50.9^ 35.1/27
50.8 and 50.85§
Di Bisceglie [17] USA No information RCT, unblinded Intention-to-treat 189/191 46.9/48.4 64/71
Escudero [18] Spain May 2001 to December 2006 Controlled Intention-to-treat 59/58 45.8/45.1 66.1/60.3
McHutchison [19] USA March 2004 to June 2006 RCT# Intention-to-treat 1,035/1,019 47.6/47.5 59.2/60.2
Ascione [20] Italy March 2004 to December 2006 RCT, unblinded Intention-to-treat 93/93 51.3/48.9° 50.6/58.8°
Lee [21] Korea May 2004 to February 2009 Controlled Intention-to-treat 21/16 53.4/53.6° 64.6/55.3°
Rumi [22] Italy September 2003 to June 2007 RCT, unblinded Intention-to-treat 91/87 51.6/52.8° 60.4/54.8

*RCT randomized controlled trial; # Random double-blinded with regard to the dose of Peg-IFN alfa-2b; ^ Male; § Female; ° All genotypes.

Coppola et al.

Coppola et al. BMC Infectious Diseases 2012 12:357   doi:10.1186/1471-2334-12-357

Open Data